Table 3.
Accuracy of circulating tumor biomarkers for gastric cancer recurrence and survival (excluding duplicate studies and those with unclear number or fewer than 20 recurrences or deaths).
| Author, year | Biomarkers | Stage | Pre-op, post-op or time of recurrence | No. recurrence/total | Sensitivity for recurrence | Specificity for recurrence | NPV for recurrence | PPV for recurrence | HR for recurrence (95% CI) | Adjusted HR (95% CI) | Mean/Median recurrence-free survival |
|---|---|---|---|---|---|---|---|---|---|---|---|
| RECURRENCE | |||||||||||
| Fang; 2016 (8) | DNA copy number (cyclophilin) | All stages | Pre-op | 129/244 | 49.6% | N/A | N/A | N/A | 1.19 (0.86–1.63) | N/A | N/A |
| SURVIVAL | |||||||||||
| Author, year | Biomarkers | Stage | Pre-op or post-op | No. deaths/total | Sensitivity for death | Specificity for death | NPV for death | PPV for death | HR for poor survival (95% CI) | Adjusted HR (95% CI) | Mean/Median survival |
| Fang; 2016 (8) | DNA copy number (cyclophilin); | All stages | Pre-op | 179/277 | N/A | N/A | N/A | N/A | N/A | N/A | High DNA levels: 39.2% (vs. 45.8%), p = 0.039 |
| DNA mutations | DNA mutations stage III-IV: 5.6% (vs. 31.5%), p = 0.028 | ||||||||||
| Balgkouranidou; 2013 (72) | Methylation: SOX17 | Operable gastric cancer | Pre-op | 38/73 | 68% | 51% | 60% | 61% | 2.0 (1.0–3.9) | 3.0 (1.2–7.8) | 37.7 months (vs. 66.9 months), p = 0.049 |
| Balgkouranidou; 2015 (71) | Methylation: APC, RASSF1A | Stage I-III | Pre-op | 38/73 |
APC: 94.7% RASSF1A: 65.8% |
N/A | N/A |
APC: 59.0% RASSF1A: 56.5% |
N/A |
APC: 4.6 (1.1-20.3) RASSF1A: Not significant |
APC: 46.0 months (vs. 85.0 months), p = 0.008 RASSF1A: 56.0 months (vs. 43.0 months), p = 0.683 |
CI, Confidence interval; HR, hazard ratio; N/A, not applicable; NPV, negative predictive value; PPV, positive predictive value; post-op, post-operative; pre-op: pre-operative.